NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

Insurance and the High Prices of Pharmaceuticals

David Besanko, David Dranove, Craig Garthwaite

NBER Working Paper No. 22353
Issued in June 2016
NBER Program(s):Health Care, Health Economics, Industrial Organization, Public Economics

We present a model in which prospective patients are liquidity constrained, and thus health insurance allows patients access to treatments and services that they otherwise would have been unable to afford. Consistent with large expansions of insurance in the U.S. (e.g., the Affordable Care Act), we assume that policies expand the set of services that must be covered by insurance. We show that the profit-maximizing price for an innovative treatment is greater in the presence of health insurance than it would be for an uninsured population. We also show that consumer surplus is less than it would be if the innovation was not covered. These results show that even in the absence of moral hazard, there are channels through which insurance can negatively affect consumer welfare. Our model also provides an economic rationale for the claim that pharmaceutical firms set prices that exceed the value their products create. We empirically examine our model's predictions by studying the pricing of oncology drugs following the 2003 passage of Medicare Part D. Prior to 2003, drugs covered under Medicare Part B had higher prices than those that would eventually be covered under Part D. In general, the trends in pricing across these categories were similar. However, after 2003 there was a far greater increase in prices for products covered under Part D, and as result, products covered by both programs were sold at similar prices. In addition, these prices were quite high compared to the value created by the products---suggesting that the forced bundle of Part D might have allowed firms to capture more value than their products created.

download in pdf format
   (491 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w22353

Users who downloaded this paper also downloaded* these:
Dranove, Garthwaite, and Hermosilla w20212 Pharmaceutical Profits and the Social Value of Innovation
Yeung, Basu, Hansen, and Sullivan w22308 Price Elasticities of Pharmaceuticals in a Value-Based-Formulary Setting
Einav, Finkelstein, and Polyakova w22277 Private Provision of Social Insurance: Drug-specific Price Elasticities and Cost Sharing in Medicare Part D
Conti and Berndt w20016 Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007
Backus and Lewis w22375 Dynamic Demand Estimation in Auction Markets
 
Publications
Activities
Meetings
NBER Videos
Themes
Data
People
About

National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us